<!DOCTYPE html>
<html>
<head>
<meta http-equiv="X-UA-Compatible" content="IE=Edge" />
<meta charset="utf-8" />
</head>

<body style="margin: 0;">

<div id="p159" style="overflow: hidden; position: relative; background-color: white; width: 1210px; height: 935px;">
<style class="shared-css" type="text/css" >
.t {
	transform-origin: bottom left;
	z-index: 2;
	position: absolute;
	white-space: pre;
	overflow: visible;
	line-height: 1.5;
}
.text-container {
	white-space: pre;
}
@supports (-webkit-touch-callout: none) {
	.text-container {
		white-space: normal;
	}
}
</style>
<style type="text/css" >

#t1_159{left:35px;bottom:24px;letter-spacing:-0.34px;word-spacing:0.13px;}
#t2_159{left:306px;bottom:30px;}
#t3_159{left:313px;bottom:24px;letter-spacing:0.16px;}
#t4_159{left:346px;bottom:30px;}
#t5_159{left:351px;bottom:24px;letter-spacing:-0.16px;word-spacing:-0.22px;}
#t6_159{left:517px;bottom:30px;}
#t7_159{left:524px;bottom:24px;letter-spacing:-0.28px;word-spacing:-0.09px;}
#t8_159{left:288px;bottom:860px;letter-spacing:0.11px;word-spacing:-0.55px;}
#t9_159{left:288px;bottom:829px;letter-spacing:0.27px;word-spacing:-0.69px;}
#ta_159{left:1115px;bottom:27px;letter-spacing:0.23px;}
#tb_159{left:35px;bottom:777px;letter-spacing:0.15px;word-spacing:0.03px;}
#tc_159{left:35px;bottom:754px;letter-spacing:0.12px;word-spacing:-0.29px;}
#td_159{left:35px;bottom:731px;letter-spacing:0.11px;word-spacing:0.07px;}
#te_159{left:35px;bottom:707px;letter-spacing:0.1px;word-spacing:-0.18px;}
#tf_159{left:530px;bottom:715px;}
#tg_159{left:576px;bottom:707px;letter-spacing:0.17px;}
#th_159{left:35px;bottom:684px;letter-spacing:0.09px;word-spacing:-0.89px;}
#ti_159{left:35px;bottom:661px;letter-spacing:0.18px;word-spacing:-0.24px;}
#tj_159{left:306px;bottom:668px;letter-spacing:0.1px;}
#tk_159{left:351px;bottom:661px;letter-spacing:0.02px;word-spacing:0.17px;}
#tl_159{left:35px;bottom:638px;letter-spacing:0.11px;word-spacing:0.08px;}
#tm_159{left:35px;bottom:614px;letter-spacing:0.08px;word-spacing:-0.26px;}
#tn_159{left:35px;bottom:591px;letter-spacing:0.13px;word-spacing:0.06px;}
#to_159{left:35px;bottom:568px;letter-spacing:0.18px;word-spacing:0.01px;}
#tp_159{left:271px;bottom:576px;letter-spacing:-0.01px;}
#tq_159{left:295px;bottom:568px;letter-spacing:0.03px;word-spacing:0.15px;}
#tr_159{left:35px;bottom:545px;letter-spacing:0.09px;word-spacing:-0.77px;}
#ts_159{left:35px;bottom:522px;letter-spacing:0.08px;word-spacing:0.1px;}
#tt_159{left:35px;bottom:498px;letter-spacing:0.09px;word-spacing:0.1px;}
#tu_159{left:35px;bottom:475px;letter-spacing:0.07px;word-spacing:0.12px;}
#tv_159{left:35px;bottom:452px;letter-spacing:0.15px;word-spacing:0.04px;}
#tw_159{left:35px;bottom:430px;letter-spacing:0.18px;word-spacing:-0.55px;}
#tx_159{left:35px;bottom:407px;letter-spacing:0.13px;word-spacing:0.05px;}
#ty_159{left:154px;bottom:414px;letter-spacing:-0.01px;}
#tz_159{left:35px;bottom:366px;letter-spacing:0.05px;word-spacing:0.14px;}
#t10_159{left:35px;bottom:343px;letter-spacing:0.1px;word-spacing:0.09px;}
#t11_159{left:35px;bottom:320px;letter-spacing:0.1px;word-spacing:-0.33px;}
#t12_159{left:35px;bottom:297px;letter-spacing:0.08px;word-spacing:-0.57px;}
#t13_159{left:35px;bottom:273px;letter-spacing:0.13px;word-spacing:0.05px;}
#t14_159{left:35px;bottom:250px;letter-spacing:0.06px;word-spacing:0.12px;}
#t15_159{left:35px;bottom:227px;letter-spacing:0.15px;word-spacing:0.03px;}
#t16_159{left:35px;bottom:204px;letter-spacing:0.1px;word-spacing:0.08px;}
#t17_159{left:35px;bottom:181px;letter-spacing:0.11px;word-spacing:-1.05px;}
#t18_159{left:35px;bottom:157px;letter-spacing:0.03px;word-spacing:0.15px;}
#t19_159{left:35px;bottom:134px;letter-spacing:0.04px;word-spacing:0.15px;}
#t1a_159{left:35px;bottom:111px;letter-spacing:0.19px;}
#t1b_159{left:270px;bottom:118px;letter-spacing:-0.01px;}
#t1c_159{left:293px;bottom:111px;letter-spacing:0.21px;word-spacing:-0.02px;}
#t1d_159{left:35px;bottom:88px;letter-spacing:-0.04px;word-spacing:0.23px;}
#t1e_159{left:35px;bottom:64px;letter-spacing:0.09px;word-spacing:0.09px;}
#t1f_159{left:618px;bottom:777px;letter-spacing:0.14px;word-spacing:-0.22px;}
#t1g_159{left:618px;bottom:754px;letter-spacing:0.16px;word-spacing:0.03px;}
#t1h_159{left:618px;bottom:731px;letter-spacing:0.07px;word-spacing:-1.12px;}
#t1i_159{left:618px;bottom:707px;letter-spacing:0.14px;word-spacing:-0.82px;}
#t1j_159{left:618px;bottom:684px;letter-spacing:0.17px;word-spacing:0.02px;}
#t1k_159{left:618px;bottom:661px;letter-spacing:0.11px;word-spacing:0.08px;}
#t1l_159{left:618px;bottom:638px;letter-spacing:0.11px;word-spacing:0.08px;}
#t1m_159{left:618px;bottom:597px;letter-spacing:0.23px;}
#t1n_159{left:618px;bottom:573px;letter-spacing:0.06px;word-spacing:0.12px;}
#t1o_159{left:618px;bottom:550px;letter-spacing:0.11px;word-spacing:-1.15px;}
#t1p_159{left:618px;bottom:526px;letter-spacing:0.12px;word-spacing:0.07px;}
#t1q_159{left:618px;bottom:503px;letter-spacing:0.12px;word-spacing:0.07px;}
#t1r_159{left:618px;bottom:480px;letter-spacing:0.06px;word-spacing:0.12px;}
#t1s_159{left:618px;bottom:457px;letter-spacing:0.02px;word-spacing:0.16px;}
#t1t_159{left:823px;bottom:457px;letter-spacing:0.19px;word-spacing:-0.01px;}
#t1u_159{left:618px;bottom:434px;letter-spacing:0.15px;word-spacing:-1.2px;}
#t1v_159{left:896px;bottom:434px;letter-spacing:-0.01px;word-spacing:-1.04px;}
#t1w_159{left:618px;bottom:410px;letter-spacing:0.09px;word-spacing:0.09px;}
#t1x_159{left:737px;bottom:418px;letter-spacing:-0.01px;}
#t1y_159{left:760px;bottom:410px;letter-spacing:0.01px;word-spacing:0.18px;}
#t1z_159{left:618px;bottom:387px;letter-spacing:0.1px;word-spacing:-0.48px;}
#t20_159{left:618px;bottom:364px;letter-spacing:0.06px;word-spacing:-0.29px;}
#t21_159{left:618px;bottom:341px;letter-spacing:0.16px;word-spacing:0.03px;}
#t22_159{left:618px;bottom:317px;letter-spacing:0.01px;word-spacing:0.17px;}
#t23_159{left:618px;bottom:294px;letter-spacing:0.05px;word-spacing:0.34px;}
#t24_159{left:618px;bottom:253px;letter-spacing:0.19px;}
#t25_159{left:618px;bottom:229px;letter-spacing:0.1px;word-spacing:-0.03px;}
#t26_159{left:618px;bottom:206px;letter-spacing:0.04px;word-spacing:0.15px;}
#t27_159{left:618px;bottom:183px;letter-spacing:0.14px;word-spacing:-0.36px;}
#t28_159{left:618px;bottom:160px;letter-spacing:0.08px;word-spacing:-0.99px;}
#t29_159{left:618px;bottom:137px;letter-spacing:0.15px;word-spacing:-1.2px;}
#t2a_159{left:853px;bottom:144px;letter-spacing:-0.01px;}
#t2b_159{left:875px;bottom:137px;letter-spacing:0.23px;word-spacing:-0.04px;}
#t2c_159{left:618px;bottom:113px;letter-spacing:0.15px;word-spacing:0.04px;}
#t2d_159{left:618px;bottom:90px;letter-spacing:0.11px;word-spacing:-0.85px;}
#t2e_159{left:618px;bottom:67px;letter-spacing:0.08px;word-spacing:-0.89px;}
#t2f_159{left:915px;bottom:74px;}
#t2g_159{left:959px;bottom:67px;letter-spacing:0.06px;word-spacing:-1.1px;}
#t2h_159{left:23px;bottom:915px;letter-spacing:-0.14px;}

.s0_159{font-size:10px;font-family:ArialMT_5tg;color:#000;}
.s1_159{font-size:6px;font-family:ArialMT_5tg;color:#000;}
.s2_159{font-size:28px;font-family:Arial-BoldMT_5te;color:#000;}
.s3_159{font-size:17px;font-family:Arial-BoldMT_5te;color:#000;}
.s4_159{font-size:17px;font-family:ArialMT_5tg;color:#000;}
.s5_159{font-size:11px;font-family:ArialMT_5tg;color:#000;}
.s6_159{font-size:17px;font-family:Arial-ItalicMT_kb;color:#000;}
.s7_159{font-size:11px;font-family:Helvetica, Arial, sans-serif;color:#000;}
</style>
<style id="fonts159" type="text/css" >

@font-face {
	font-family: Arial-BoldMT_5te;
	src: url("fonts/Arial-BoldMT_5te.woff") format("woff");
}

@font-face {
	font-family: Arial-ItalicMT_kb;
	src: url("fonts/Arial-ItalicMT_kb.woff") format("woff");
}

@font-face {
	font-family: ArialMT_5tg;
	src: url("fonts/ArialMT_5tg.woff") format("woff");
}

</style>
<div id="pg159Overlay" style="width:100%; height:100%; position:absolute; z-index:1; background-color:rgba(0,0,0,0); -webkit-user-select: none;"></div>
<div id="pg159" style="-webkit-user-select: none;"><object width="1210" height="935" data="159/159.svg" type="image/svg+xml" id="pdf159" style="width:1210px; height:935px; z-index: 0;"></object></div>
<div class="text-container"><span id="t1_159" class="t s0_159">Version 4.2024 © 2024 National Comprehensive Cancer Network </span>
<span id="t2_159" class="t s1_159">© </span>
<span id="t3_159" class="t s0_159">(NCCN </span>
<span id="t4_159" class="t s1_159">© </span>
<span id="t5_159" class="t s0_159">), All rights reserved. NCCN Guidelines </span>
<span id="t6_159" class="t s1_159">® </span>
<span id="t7_159" class="t s0_159">and this illustration may not be reproduced in any form without the express written permission of NCCN. </span>
<span id="t8_159" class="t s2_159">NCCN Guidelines Version 4.2024 </span>
<span id="t9_159" class="t s2_159">Head and Neck Cancers </span>
<span id="ta_159" class="t s3_159">MS-18 </span>
<span id="tb_159" class="t s4_159">However, the planning and delivery of PBT continues to develop, and </span>
<span id="tc_159" class="t s4_159">occasional fatal outcomes have been reported with proton therapy due to </span>
<span id="td_159" class="t s4_159">uncertainties associated with these evolving technologies, including a </span>
<span id="te_159" class="t s4_159">small number of deaths secondary to brainstem injury in children. </span>
<span id="tf_159" class="t s5_159">248-250 </span>
<span id="tg_159" class="t s4_159">In </span>
<span id="th_159" class="t s4_159">general, clinicians have reported low rates of serious toxicities when using </span>
<span id="ti_159" class="t s4_159">strict dose limits for proton therapy. </span>
<span id="tj_159" class="t s5_159">240,251 </span>
<span id="tk_159" class="t s4_159">However, disadvantageous and </span>
<span id="tl_159" class="t s4_159">advantageous outcomes continue to be more fully documented as the </span>
<span id="tm_159" class="t s4_159">clinical experience accrues. A case series including 122 patients with oral </span>
<span id="tn_159" class="t s4_159">or oropharyngeal cancer who were treated with PBT showed that 10.6% </span>
<span id="to_159" class="t s4_159">developed osteoradionecrosis. </span>
<span id="tp_159" class="t s5_159">252 </span>
<span id="tq_159" class="t s4_159">In patients who have tumors that are </span>
<span id="tr_159" class="t s4_159">periocular in location and/or invade the orbit, skull base, and/or cavernous </span>
<span id="ts_159" class="t s4_159">sinus, and/or tumors that extend intracranially or exhibit extensive </span>
<span id="tt_159" class="t s4_159">perineural invasion, highly conformal dose distributions are crucial, and </span>
<span id="tu_159" class="t s4_159">proton therapy may provide certain unique advantages. In patients with </span>
<span id="tv_159" class="t s4_159">these types of tumors who are being treated with curative intent and/or </span>
<span id="tw_159" class="t s4_159">have long life expectancies, PBT may offer the opportunity for lower late- </span>
<span id="tx_159" class="t s4_159">onset toxicities. </span>
<span id="ty_159" class="t s5_159">253 </span>
<span id="tz_159" class="t s4_159">As described above, nonrandomized institutional reports and a small </span>
<span id="t10_159" class="t s4_159">number of systematic reviews have shown that PBT is safe to use in a </span>
<span id="t11_159" class="t s4_159">controlled setting. However, without high-quality prospective comparative </span>
<span id="t12_159" class="t s4_159">data, it is premature to conclude that proton therapy has been established </span>
<span id="t13_159" class="t s4_159">as superior to other modern radiation techniques such as IMRT, </span>
<span id="t14_159" class="t s4_159">particularly with regard to tumor control. An accurate comparison of </span>
<span id="t15_159" class="t s4_159">benefits to other RT options would ideally take place in the controlled </span>
<span id="t16_159" class="t s4_159">setting of randomized clinical trials. Given the unique abilities of PBT to </span>
<span id="t17_159" class="t s4_159">treat more difficult tumors, randomized trials may not be possible for some </span>
<span id="t18_159" class="t s4_159">scenarios. In these cases, an alternative approach may be to develop </span>
<span id="t19_159" class="t s4_159">prospectively maintained databases to raise the quality of institutional </span>
<span id="t1a_159" class="t s4_159">reports of clinical experiences. </span>
<span id="t1b_159" class="t s5_159">250 </span>
<span id="t1c_159" class="t s4_159">In cancers of the oropharynx, </span>
<span id="t1d_159" class="t s4_159">supraglottic larynx, nasopharynx, paranasal sinus, and salivary glands, as </span>
<span id="t1e_159" class="t s4_159">well as MM, and unknown primary tumors of the H&amp;N, the panel agrees </span>
<span id="t1f_159" class="t s4_159">that proton therapy should be considered when normal tissue constraints </span>
<span id="t1g_159" class="t s4_159">cannot be met by photon-based therapy, or when photon-based therapy </span>
<span id="t1h_159" class="t s4_159">causes compromise of standard radiation dosing to tumor or postoperative </span>
<span id="t1i_159" class="t s4_159">volumes. The panel supports ongoing efforts to develop models to predict </span>
<span id="t1j_159" class="t s4_159">which patients would benefit the most from proton therapy and the </span>
<span id="t1k_159" class="t s4_159">development of higher-level and/or randomized data demonstrating </span>
<span id="t1l_159" class="t s4_159">greater efficacy or meaningful QOL gains potentially achieved with PBT. </span>
<span id="t1m_159" class="t s6_159">Brachytherapy </span>
<span id="t1n_159" class="t s4_159">Brachytherapy is a uniquely conformal modality that is considered to be </span>
<span id="t1o_159" class="t s4_159">effective and safe when delivered by an experienced team of practitioners. </span>
<span id="t1p_159" class="t s4_159">Brachytherapy is now necessary less often because of improved local </span>
<span id="t1q_159" class="t s4_159">control and lower toxicities obtained with IMRT with or without systemic </span>
<span id="t1r_159" class="t s4_159">therapy. However, brachytherapy still has an important role in cancers of </span>
<span id="t1s_159" class="t s4_159">the lip and oral cavity (see </span><span id="t1t_159" class="t s6_159">Cancer of the Oral Cavity [Including Mucosal </span>
<span id="t1u_159" class="t s6_159">Lip]: Principles of Radiation Therapy </span><span id="t1v_159" class="t s4_159">in the NCCN Guidelines for Head and </span>
<span id="t1w_159" class="t s4_159">Neck Cancers). </span>
<span id="t1x_159" class="t s5_159">254 </span>
<span id="t1y_159" class="t s4_159">Brachytherapy may have a role in other select clinical </span>
<span id="t1z_159" class="t s4_159">scenarios such as reirradiation, as a boost for highly refractory disease or </span>
<span id="t20_159" class="t s4_159">a positive surgical margin, or when extremely conformal radiation delivery </span>
<span id="t21_159" class="t s4_159">is needed to a very well-defined tumor location; these are unique </span>
<span id="t22_159" class="t s4_159">situations arising from challenging clinical circumstances and limited </span>
<span id="t23_159" class="t s4_159">availability of head and neck brachytherapy expertise. </span>
<span id="t24_159" class="t s6_159">Stereotactic Body Radiation Therapy </span>
<span id="t25_159" class="t s4_159">Stereotactic body RT (SBRT) is an advanced technique of external beam </span>
<span id="t26_159" class="t s4_159">RT (EBRT) that delivers large ablative doses of radiation in a limited </span>
<span id="t27_159" class="t s4_159">number of fractions. Advantages of SBRT include shorter treatment time, </span>
<span id="t28_159" class="t s4_159">promising local control rates, and higher but acceptable toxicity depending </span>
<span id="t29_159" class="t s4_159">on the specific location treated. </span>
<span id="t2a_159" class="t s5_159">255 </span>
<span id="t2b_159" class="t s4_159">There is currently insufficient evidence </span>
<span id="t2c_159" class="t s4_159">to recommend SBRT routinely for treatment of H&amp;N cancers, but the </span>
<span id="t2d_159" class="t s4_159">NCCN Panel acknowledges that it might be beneficial in the settings of re- </span>
<span id="t2e_159" class="t s4_159">irradiation, palliation, or for older adults. </span>
<span id="t2f_159" class="t s5_159">256-258 </span>
<span id="t2g_159" class="t s4_159">SBRT has been reported the </span>
<span id="t2h_159" class="t s7_159">Printed by Fredd Merc on 8/29/2024 4:45:54 AM. For personal use only. Not approved for distribution. Copyright © 2024 National Comprehensive Cancer Network, Inc., All Rights Reserved. </span></div>

</div>
</body>
</html>
